WO1998040033A2 - In situ formed stent - Google Patents
In situ formed stent Download PDFInfo
- Publication number
- WO1998040033A2 WO1998040033A2 PCT/US1998/004779 US9804779W WO9840033A2 WO 1998040033 A2 WO1998040033 A2 WO 1998040033A2 US 9804779 W US9804779 W US 9804779W WO 9840033 A2 WO9840033 A2 WO 9840033A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- composition
- fluent
- body lumen
- energy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/129—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/0091—Handpieces of the surgical instrument or device
- A61B2018/00916—Handpieces of the surgical instrument or device with means for switching or controlling the main function of the instrument or device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/94—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
- A61F2/945—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place hardenable, e.g. stents formed in situ
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/3008—Properties of materials and coating materials radio-opaque, e.g. radio-opaque markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
- A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
- A61F2002/30581—Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid
- A61F2002/30583—Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid filled with hardenable fluid, e.g. curable in-situ
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0085—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof hardenable in situ, e.g. epoxy resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/44—Radioisotopes, radionuclides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
Definitions
- the present invention relates generally to stents for body lumens. More specifically, the present invention relates to stents created in situ within a body lumen through the conversion of a fluent material to a non- fluent material where the fluent material is delivered to the body lumen in a fluent state.
- Angioplasty is a procedure for treating blood vessels or arteries which have become narrowed by plaque deposits.
- a catheter comprising an inflatable balloon is advanced along a path of travel through the artery to a narrowed or stenosed region.
- the balloon is inflated at the stenosed region of the artery causing it to be expanded.
- the balloon is then deflated and withdrawn.
- the effect of inflating a balloon against a narrowed arterial wall typically produces injuries.
- an angioplasty balloon When an angioplasty balloon is inflated, the single layer of cells constituting the endothelial lining typically are torn away. Also, the inflation of the angioplasty balloon may induce fissures or other injuries to the arterial wall. The loss of endothelial cells and injury to the arterial wall create an irregular surface. Such tears and unconformities in the arterial wall, along with the loss of the endothelial layer, activate the coagulation system. This in turn may form sites for promoting the growth of blood clots, which then again occlude and narrow the artery.
- Conventional cardiology procedures include the introduction of a stent to a target site in a blood vessel after balloon angioplasty has been performed to provide structural support to the vessel.
- Conventional stents typically are fabricated of metal or plastic and include a central lumen to permit the flow of blood through the blood vessel.
- the metal or plastic composition is necessary to provide sufficient rigidity to hold the blood vessel open.
- Conventional stents are fabricated outside of the body and introduced into the blood vessel on the outside of a catheter. The stent is then advanced along a path of travel to the point of intervention. As the stent is advanced through the blood vessel, the inherent stiffness and pre-formed configuration of the stent often causes trauma to the vascular wall and the endothelial lining. The pre-formed stent can also be lost in the vessel.
- a new type of stent which can be introduced to a target site in body lumen substantially without trauma and without contaminating the target site or any lesion with thrombogenic material which would cause trauma, constriction and/or restenosis.
- an improved stent which once placed in the body lumen can reduce or prevent restenosis and at the same time not create a permanent danger to the patient in the event the stent is dislodged.
- a stent and a method for delivering the stent which can be considerably downsized over what is presently available and which can be delivered to a target site without injury to the delicate, single layer of cells constituting the endothelial lining.
- body lumens include but are not limited to blood vessels (veins, arteries), ducts and vas.
- the shaped articles include a lumen which allows biological material which would otherwise be flowing through the body lumen to flow through the shaped article.
- the formed shaped articles can perform a variety of non-mechanical functions. Examples of these non-mechanical functions include, but are not limited to providing a protective layer, proving a barrier layer, delivering therapeutic agents, delivering radioactive energy, repairing and sealing a body lumen and providing a smooth interior surface to the body lumen.
- Another object of the invention is to provide a device, a method, and a composition for forming a stent in a body lumen in situ from a fluent composition that is provided in a fluent state through the body lumen to the site of stent formation.
- the body lumen and stent forming device form a mold space within which the fluent composition is transformed into a nonfluent composition in the shape of a stent.
- Another object of the invention is to provide a device, a method, and a composition for forming a fenestrated stent in situ in a body lumen from a fluent composition that is provided in a fluent state through the body lumen to the site of stent formation.
- the body lumen and stent forming device form a mold space within which the fluent composition is transformed into a nonfluent composition in the shape of a stent with a series of fenestrations.
- Another object of the invention is to provide a device, a method, and a composition for forming a stent in situ in a body lumen from a fluent composition that is provided in a fluent state through the body lumen to the site of stent formation where energy is delivered at the site of stent formation to cause the fluent composition to become transformed into a nonfluent composition.
- energy is delivered via a catheter.
- energy is delivered via a guidewire.
- the energy is electromagnetic energy and more specifically either RF or microwave energy. It is a further object of the invention to provide a device, a method, and a composition for forming stents in situ in the human vascular system, particularly coronary arteries.
- VEGF vascular endothelial growth factor
- the catheter preferably also includes one or more lumens for delivering a material to wash the mold space or aspirating the mold space to facilitate delivery of the fluent pre-stent material within the mold space.
- Figures 1A-1D illustrate isometric views of four different fenestrated stents, representing embodiments of the invention.
- Figures 2A-2H illustrate isometric views of four different devices ( Figures 2A, 2C, 2E, 2G) for making fenestrated stents in situ and the four corresponding stents ( Figures 2B, 2D, 2F, 2H) made from the four depicted devices, representing embodiments of the invention.
- Figures 3A-3K illustrate schematic cross section views that depict sequential steps composing a method for making a fenestrated stent, representing an embodiment of the invention.
- Figure 4A illustrates a cross section view of a device for making a fenestrated stent, representing an embodiment of the invention.
- Figure 4B illustrates a schematic view of a first system for applying energy to a fluent pre-stent material to effect a change of state from a fluent state to a nonfluent state, representing an embodiment of the invention.
- Figure 4C illustrates a schematic view of a second system for applying energy to a fluent pre-stent material, representing an embodiment of the invention.
- Figure 4D illustrates a schematic view of a third system for applying energy to a fluent pre-stent material, representing an embodiment of the invention.
- Figure 4E illustrates a schematic diagram of a system for adaptive feedback and automated control of a method for applying energy to cure a fluent pre-stent material, representing an embodiment of the invention.
- Figure 5A illustrates a cross-sectional view of a first system for advancing and steering a catheter along a path of travel in a body lumen, representing an embodiment of the invention.
- Figure 5B illustrates a cross-sectional view of a second system for advancing and steering a catheter along a path of travel in a body lumen, representing an embodiment of the invention.
- Figure 6A illustrates a side view of a device for making a spiral fenestrated stent, representing an embodiment of the invention.
- Figure 6B illustrates a cross-sectional view of the device depicted in Figure 6A.
- Figure 7 illustrates side, a partial sectional view of a device for forming a stent, representing an embodiment of the invention.
- Figure 8A illustrates a side view of a catheter for forming a stent, representing an embodiment of the invention.
- Figure 8B illustrates an expanded sectional view of a portion of the device shown in Figure 8A.
- Figure 9 illustrates a perspective, partial section view of a device for forming a stent, representing an embodiment of the invention.
- Figure 10A illustrates a cross-sectional view of a perfusion valve catheter system for forming a stent in a collapsed state with the perfusion valves closed, representing an embodiment of the invention.
- Figure 10B illustrates the system of Figure 10A in an expanded state with the perfusion valves open.
- Figure 11 illustrates a perspective partially exploded view of a device for forming a stent, representing an embodiment of the invention.
- Figures 12A-12B illustrate a distal catheter body with an aspiration lumen and port.
- Figures 13A-13F illustrate schematic sectional views that depict sequential steps composing a method for breaking plaque and forming a stent, representing an embodiment of the invention.
- Figure 14 illustrates a perspective schematic view of a porous stent, representing an embodiment of the present invention.
- Figure 15 illustrates a schematic sectional view of the wall of a porous stent adjacent wall of a body lumen representing an embodiment of the present invention.
- Figures 16A-16B illustrate perspective views of stents, including electrodes.
- Figures 17A-17G illustrate schematic views of a method, device and composition for forming a stent, representing an embodiment of the invention.
- Figures 18A-18D illustrate schematic perspective views of a device, method, and composition for forming a stent, representing an embodiment of the invention.
- Figure 19A illustrates a schematic sectional view of a device for forming a stent, representing an embodiment of the invention.
- Figure 19B illustrates a schematic perspective view of a device for forming a stent, representing an embodiment of the invention.
- Figures 20A-20C illustrate an embodiment of a multilumen balloon which can be used in the distal catheter body of the present invention.
- Figure 20A illustrates the distal catheter body in a deflated state with cross sections A-A and B-B indicated.
- Figure 20B illustrates cross section A-A.
- Figures 20C illustrates cross section B-B.
- Figure 21 illustrates a preferred positioning for a thermocouple junction.
- Figures 22A-22D illustrate schematic views of a device for forming serial stents, representing an embodiment of the invention.
- Figure 23 illustrates a stent formed in situ which includes an agent for delivering radioactive energy.
- the present invention relates to a stent formed in a body lumen.
- the stent includes an article shaped to provide support to a section of a body lumen and allow biological material which would otherwise flow through the body lumen to flow through the article, the article including a non-fluent stent composition in intimate contact with the section of the body lumen which was delivered through the body lumen to the section as a fluent pre-stent composition and transformed adjacent the section of the body lumen to the non-fluent stent composition.
- the stent in another embodiment, includes an article shaped to provide support to a section of a body lumen and allow biological material which would otherwise flow through the body lumen to flow through the article, the article being formed by delivering a fluent pre-stent composition and an energy susceptible composition to a mold space defined by a section of a body lumen and a fluent pre-stent composition delivery device, and transforming the fluent pre-stent composition to a non-fluent stent composition within the mold space by introducing a form of energy which is preferentially absorbed by the energy susceptible composition.
- the stent includes an article shaped to provide support to a section of a body lumen and allow biological material which would otherwise flow through the body lumen to flow through the article, the article being formed by transforming a fluent pre-stent composition to a non-fluent stent composition using an energy susceptible composition and a form of energy which is preferentially absorbed by the energy susceptible composition.
- the stent is formed using a chemical agent which catalyzes the fluent to non-fluent transformation of the pre- stent material.
- the present invention also relates to a fenestrated stent formed in a body lumen.
- the fenestrated stent includes an article shaped to provide support to a section of a body lumen and allow biological material which would otherwise flow through the body lumen to flow through the article, the article being formed with fenestrations by delivering a fluent pre-stent composition to a mold space defined by a section of a body lumen and a fluent pre-stent composition delivery device having members which define the fenestrations, and transforming the fluent pre-stent composition to a non-fluent stent composition within the mold space.
- the fenestrated stent includes an article shaped to provide support to a section of a body lumen, allow biological material which would otherwise flow through the body lumen to flow through the article, and include fenestrations, the fenestrated article including a non-fluent stent composition in intimate contact with the section of the body lumen which was delivered through the body lumen to the section as a fluent pre-stent composition and transformed adjacent the section to the non-fluent stent composition.
- the stent in yet another embodiment, includes an article shaped to provide support to a section of a body lumen and allow biological material which would otherwise flow through the body lumen to flow through the article, the article including a non-fluent stent composition in intimate contact with the section of the body lumen which was delivered through the body lumen to the section as a fluent pre- stent composition and transformed adjacent the section to the non-fluent stent composition; and a bioresorbable composition dispersed among the article which when bioresorbed leave fenestrations in the article.
- the stent may have one or more of the following features: the stent defines a stent lumen having first and second ends, each end having a diameter, a section of the stent lumen positioned between the first and second ends having a diameter which is larger than the diameters of the lumen at the first and second ends; the non-fluent stent composition includes an energy susceptible composition; the non-fluent stent composition includes a microwave energy susceptible composition; the non-fluent stent composition includes a material for dilating a body lumen, preferably magnesium sulfate; the article is shaped to interpenetrate fissures at the section of the body lumen; the non-fluent stent composition includes linkages selected from the group consisting of carbonate, amide, peptide, and urethanes, ester, urea, ether, amino, thio, hydrocarbonyl, sulfony
- the present invention also relates to a composition for forming a stent in a body lumen.
- the composition includes a first fluent composition which can be transformed into a second non- fluent composition upon the application of thermal energy; and an energy susceptible composition admixed with the first fluent composition which preferentially absorbs microwave energy and catalyzes the transformation of the first fluent composition to the second non-fluent composition upon the application of microwave energy.
- the composition includes an agent capable of delivering radioactive energy that can be used to prevent restenosis where the stent formed using the material is positioned. Any radioactive material may be used.
- the present invention also relates to a catheter for forming a stent in a body lumen.
- the catheter includes a distal catheter body having one or more fluent pre-stent composition delivery ports; one or more expandable members attached to the distal catheter body for occluding proximal and distal sections of a body lumen so as to define a mold space therebetween and for radially expanding the body lumen within the mold space; and a lumen for delivering a fluent pre-stent composition from outside the body lumen to the expanded mold space through the one or more delivery ports.
- the catheter in another embodiment, includes a distal catheter body having one or more fluent pre-stent composition delivery ports; one or more expandable members attached to the distal catheter body for occluding proximal and distal sections of a body lumen so as to define a mold space therebetween; one or more members extending from the distal catheter body to define a fenestration pattern in the mold space; a lumen for delivering a fluent pre-stent composition from outside the body lumen to the expanded mold space through the one or more delivery ports; radioopaque material, preferably in the form of a ring, positioned proximal to the proximal expandable member and distal to the distal expandable member to allow for visualization of the position of a distal catheter body in a body lumen; and an energy delivery mechanism for delivering energy into the expanded mold space to accelerate a transformation of the fluent pre- stent composition to a non-fluent stent composition.
- the catheter is for forming fenestrated stents and includes a distal catheter body having one or more fluent pre-stent composition delivery ports; one or more expandable members attached to the distal catheter body for occluding proximal and distal sections of a body lumen so as to define a mold space therebetween; one or more members extending from the distal catheter body to define a fenestration pattern in the mold space which detach from the distal catheter body after stent formation; a lumen for delivering a fluent pre-stent composition from outside the body lumen to the expanded mold space through the one or more delivery ports; and an energy delivery mechanism for delivering energy into the expanded mold space to initiate or accelerate a transformation of the fluent pre-stent composition to a non-fluent stent composition.
- the catheter may have one or more of the following features: the one or more expandable members create a mold space which is narrower at the proximal and distal sections of the body lumen than between the proximal and distal sections; the catheter further includes an energy delivery mechanism for delivering energy into the expanded mold space to initiate or accelerate a transformation of the fluent pre-stent composition to a non-fluent stent composition; the catheter further includes an energy delivery mechanism which is attached to the distal catheter body; the catheter further includes an energy delivery mechanism which is movable relative to the distal catheter body; the catheter further includes an energy delivery mechanism which is attached to a guide wire; the catheter further includes an energy delivery mechanism which delivers RF energy; the catheter further includes an energy delivery mechanism which delivers microwave energy; the catheter includes a steerable tip distal to the distal catheter body; the catheter includes a semi-movable guidewire tip; the catheter further includes an expandable member for performing balloon angi
- the present invention also relates to methods for forming a stent within a body lumen.
- the method includes advancing a distal catheter body within a body lumen to a section of the body lumen at which a stent is to be formed; expanding one or more expandable members attached to the distal catheter body such that sections of the body lumen proximal and distal to the stent formation section of the body lumen are occluded, the distal catheter body in combination with the body lumen defining a mold space; delivering a fluent pre-stent composition within the mold space from outside the body lumen such that the pre-stent composition is continuously in fluent state during pre-stent composition delivery from outside the body lumen to the mold space; and transforming the fluent pre-stent composition to a non- fluent stent composition to form a stent within the mold space.
- the method includes advancing a distal catheter body within a body lumen to a section of the body lumen at which a stent is to be formed; expanding one or more expandable members attached to the distal catheter body such that sections of the body lumen proximal and distal to the stent formation section of the body lumen are occluded, the distal catheter body in combination with the body lumen defining a mold space; delivering a fluent pre-stent composition within the mold space from outside the body lumen such that the pre-stent composition is continuously in fluent state during pre- stent composition delivery from outside the body lumen to the mold space; and delivering thermal or electromagnetic energy, particularly Rf or microwave energy, within the mold space to initiate or accelerate the transformation transforming the fluent pre-stent composition to a non- fluent stent composition to form a stent within the mold space.
- the method includes advancing a distal catheter body within a body lumen to a section of the body lumen at which a stent is to be formed; expanding one or more expandable members attached to the distal catheter body such that sections of the body lumen proximal and distal to the stent formation section of the body lumen are occluded, the distal catheter body in combination with the body lumen defining a mold space, the distal catheter body including one or more members extending from the distal catheter body which define a fenestration pattern within the mold space; delivering a fluent pre-stent composition within the mold space from outside the body lumen such that the pre-stent composition is continuously in fluent state during pre-stent composition delivery from outside the body lumen to the mold space; and transforming the fluent pre-stent composition to a non- fluent stent composition to form a fenestrated stent within the mold space.
- the method includes advancing a distal catheter body within a body lumen to a section of the body lumen at which a stent is to be formed; expanding one or more expandable members attached to the distal catheter body such that sections of the body lumen proximal and distal to the stent formation section of the body lumen are occluded, the distal catheter body in combination with the body lumen defining a mold space, the distal catheter body including one or more detachable members extending from the distal catheter body which define a fenestration pattern within the mold space; delivering a fluent pre-stent composition within the mold space from outside the body lumen such that the pre-stent composition is continuously in fluent state during pre-stent composition delivery from outside the body lumen to the mold space; transforming the fiuent pre- stent composition to a non-fluent stent composition to form a fenestrated stent within the mold space; and detaching the one or more fenestration pattern defining
- the method can optionally include one or more of the following addition steps: radially expanding the stent formation section of the body lumen prior to the transforming step; performing balloon angioplasty prior to expanding the one or more expandable members; delivering energy within the mold space to initiate or accelerate the transformation; providing aspiration to the mold space to facilitate delivery of the fluent pre-stent composition to the mold space; washing the mold space before delivering the pre-stent composition; washing the mold space after forming the stent; providing perfusion during occlusion of the body lumen; and providing bypass by opening a bypass lumen in the distal catheter body by expanding the one or more expandable members.
- the members can be bioresorbable and the method can further include the step of bioresorbing the one or more members to leave fenestrations in the stent. Bioresorption of the bioresorbable composition can also leave pores in the stent for the diffusion of biological material therethrough.
- the method can also include the step of moving the distal catheter body from the section of the body lumen at which the stent was formed, the one or more fenestration pattern defining members being detached in the process of moving the distal catheter body.
- the one or more detachable fenestration pattern defining members can also be separated from the fenestrated stent in the process of moving the distal catheter body.
- the present invention relates to devices, methods, and compositions for forming shaped articles in a body lumen in situ.
- body lumens include, but are not limited to vessels (vein, arteries), ducts, and vas. Particular examples include narrowed or stenosed arteries or veins and body lumens with an aneurism.
- the shaped articles include a lumen which allows biological material which would otherwise be flowing through the body lumen to flow through the shaped article.
- the shaped article is formed in a body lumen in situ from a fluent composition that is provided in a fluent state through the body lumen to the site of the shaped article's formation.
- the body lumen forms a portion of a mold space within the body lumen within which the fluent composition is transformed into a non-fluent composition in the shape of the shaped article.
- a device relates to a catheter for minimally invasively forming the shaped article in the body lumen.
- a method according to the present invention relates to positioning the catheter in the body lumen and then delivering a fluent composition via the catheter through the body lumen to the site of the shaped article's formation.
- the catheter in combination with the body lumen form a mold space within the body lumen within which the fluent composition is transformed into a nonfluent composition in the shape of the shaped article.
- Energy of a chemical catalyst may be used to initiate or accelerate this transformation.
- the shaped article is a stent which is formed by expanding at least one balloon, deploying a fluent pre-stent composition from within the catheter to the site where the stent is to be formed, transforming the fluent pre-stent composition into a non-fluent stent composition, and deflating the at least one balloon.
- energy or a chemical catalyst is introduced to cause the transformation of the fluent pre-stent composition to a non-fluent stent composition.
- the present invention can also be used to form fenestrated stents.
- fenestrated stent refers to a generally tubularly shaped article for lining the inner lumenal surface of a body lumen which includes one or more holes (fenestrations) along the wall of the tubular article.
- the fenestrations of such stents can have any shape including, but not limited to, geometric shapes such as polygons (e.g., squares, rectangles, and diamonds), curved shapes such as circles and ellipses, and irregular shapes.
- the fenestrations may also result in the stent taking the form of a spiral, helix, double helix, or spiral, with, or without, circular end caps.
- any fenestrated stent which may be formed in situ using a catheter according to the present invention is intended to fall within the scope of the present invention.
- Figures 1 A-1 D illustrate a series of different fenestrated stent designs. These stent designs are complimentary to the shape of the devices that form them.
- the stent designs illustrated in Figures 1 A-1 D are intended to be illustrative of the numerous different fenestrated stent designs which are possible according to the invention and are not intended to be limiting.
- a fenestrated stent is formed within a body lumen by the in situ conversion of a fluent pre-stent composition to a non-fluent stent composition.
- the shape of the fenestrated stent is defined by the inter-relationship between a distal catheter body on a catheter according to the present invention and the body lumen in which the catheter is positioned, the body lumen and distal catheter body defining a mold space for forming the stent.
- the fluent pre-stent composition is provided within the mold space and then converted into a non-fluent stent composition.
- the fenestrated stents may be in the form of a cylinder with one or more holes in the cylinder's wall.
- the stent may be in the form of a spiral.
- a stent without fenestrations can also be made according to the method of the present invention using a device which does not have members for defining the fenestrations in the mold space.
- Figures 2A, 2C, 2E and 2G illustrate four different configurations for a distal catheter body 29 for forming a fenestrated stent.
- the body 29 functions as a device having a patterned surface 18 with members
- the body may be advanced within a vessel using a guide wire 35 or may be fixed to the catheter (not shown).
- the distal catheter body When used in combination with the interior of a body lumen, the distal catheter body creates a mold for forming fenestrated stents such as those illustrated in Figures 2B, 2D,
- FIGS. 2F and 2H Illustrated in Figures 2B, 2D, 2F and 2H are cut-away views of vessel lumens 22 where a stent 28 has been formed with fenestrations 39 by the distal catheter body 29.
- the catheter includes a mechanism for delivering energy to cause or to enhance the rate of conversion of the fluent pre-stent composition to a non-fluent stent composition.
- the energy delivery mechanism may optionally be attached to the distal catheter body 29 or the guide wire 35.
- the energy delivery mechanism may be designed to deliver one or more different types of energy including but not limited to electromagnetic radiation (RF, microwave, ultraviolet light, visible light, laser), ultrasound, or any other type of energy which can catalyze the transformation of the fluent pre-stent composition to a non-fluent stent composition.
- the energy delivery mechanism is an antenna which provides microwave (MW) energy to the fluent pre-stent composition and converts the fluent pre-stent material to a non-fluent stent composition in situ.
- the antenna broadcasts microwave (MW) energy into a predetermined volume of space with a predetermined energy density. The amount of microwave energy delivered may be based on the volume of mold space.
- the antenna system can be located on the distal catheter body. Alternatively, the antenna can be located on a guide wire which passes through the distal catheter body. In this embodiment, the guide wire performs the dual functions of operating as a guide wire and as an antenna.
- a micro coaxial cable is used to conduct MW energy from a
- MW generator to the broadcast antenna system on either the distal catheter body or the guide wire.
- the distal catheter body 29 may also include an expandable balloon 37 which forms part of the mold cavity.
- the expandable balloon 37 is in fluidic communication with a reservoir of fluent pre-stent composition proximal to the distal catheter body (not shown).
- the expandable balloon 37 contains one or more holes or pores 33 for delivering the fluent pre-stent composition into the mold space or cavity through the balloon.
- the one or more holes may optionally be part of a micro porous membrane (MPM).
- the diameter of the holes in the expandable balloon optionally expand as a function of the degree of expansion or inflation of the balloon, such that by controlling the pressure applied to fluent pre-stent composition, the diameter of holes in the balloon can be controlled.
- a non-expandable (i.e., nonconformal) balloon may be included inside the expandable balloon 35.
- Inflation of the non-expandable balloon with fluid or gas via the multi lumen catheter can be used to apply pressure to the interior wall of the body lumen, such as is required in angioplasty procedures to break plaque.
- the method can include forming, molding, and/or casting the fluent pre-stent composition into the shape of a stent prior to the fluent - non-fluent transformation using a combination of the body lumen and the catheter distal body.
- the method includes advancing a catheter distal body including an expandable member such as a balloon to a position where stent deployment is desired.
- the surface of the expandable member provides the compliment to the stent design desired and forms a mold cavity in combination with the intraluminal surface.
- the expandable member is expanded to form a mold space in combination with the intraluminal surface.
- Fluent pre-stent material is then translated (i.e., conducted, or pumped, or forced) to the mold space defined by the body lumen and distal catheter body.
- the fluent pre- stent material is translated to the mold space through the distal catheter body via the catheter.
- the mold space may be aspirated by the catheter to facilitate the delivery of material into the mold space.
- Energy or a chemical catalyst sufficent to initiate or accelerate the fluent pre-stent composition to transform to a non-fluent stent composition is introduced.
- a threshold level of microwave energy is applied via an antenna portion of the guide wire located in a central portion of the distal catheter body to transform the fluent pre-stent composition to a non-fluent stent composition.
- the antenna may alternatively be positioned on the catheter distal body.
- an optional step of inflating the inner non-expansible balloon to contact an artery intimal surface and break any plaque thereon may be interposed between the steps of advancing and initially translating above.
- any plaque debris will be preferentially encased in the non-fluent stent material following the transformation of the fluent composition to a non-fluent composition, i.e., a stent.
- a fenestrated stent 28 is formed by a catheter 20 by the following steps.
- the catheter 20 includes a distal catheter body 29 at which the stent is formed and a hollow tube 31 with a central lumen 33 for delivering the fluent pre-stent composition 26 to the distal catheter body 29 for making the stent.
- the catheter tube is attached to a supply of the fluent pre- stent composition (not shown).
- the supply can be located within the body lumen being treated, or outside the body lumen, preferably outside the body entirely. In the later case, the supply can be large and include a mechanical pump for injecting the fluent pre-stent composition, such as, for example, a screw activated piston.
- the distal catheter body 29 has a patterned surface 18 with members 19 extending from the surface for forming fenestrations. Positioned between the members are pores 33 in the distal catheter body 29 for the delivery of fluent pre-stent material to a mold space defined between the surface 18 and a body lumen 22 in which the catheter body 29 is positioned.
- a distal catheter body 29 having a patterned surface 18 with members 19 extending from the surface for forming fenestrations in the in situ formed stent is introduced to a desired region 21 of the body lumen 22.
- the catheter can be advanced along the path of travel by a guide wire 35 as shown, or by any of various well known methods.
- body lumen 22 may be a blood vessel which is partially occluded due to the accumulation of plaque 23 on the lumen walls.
- the catheter 20 preferably has a flexible, pliant nature and a low coefficient of friction in order to minimize or substantially eliminate trauma to the vessel wall as the catheter 20 is advanced to region 21.
- the distal catheter body 29 serves to isolate the region 21 of the body lumen 22 and define a cylindrical moid 23 within that region 21 using the lumen 22 as the other mold wall for forming the fenestrated stent.
- the lumen 22 defines at least one surface of a mold space. This may be accomplished, for example, by using dual balloons 24, 25 which occlude the lumen 22 both upstream and downstream of the region 21 of the lumen 22 to be isolated. Other mechanisms for isolating region 21 may also be employed.
- region 21 is isolated (e.g., fluid flow into and out of the region is prevented)
- the distal catheter body 29 may include a central mechanism for expanding the region 21 of the vessel lumen 22.
- the catheter may include a central balloon 27 for performing balloon angioplasty on the vessel.
- the overall catheter can include a balloon 45 which is coaxially moveable within the distal catheter body 29 and capable of performing balloon angioplasty on the vessel.
- the balloon 45 can be used to expand the distal catheter body 29.
- the balloon 45 can be positioned distal to the distal catheter body 29 and be used to perform balloon angioplasty on the vessel distal to the distal catheter body 29.
- Other mechanisms for expanding the region 21 of the lumen 22 to be treated may also be used.
- expansion of the region 21 of the lumen 22 to be treated may be preferred with regard to the in situ formation of a fenestrated stent.
- the fenestrated stent is formed by using the distal catheter body 29 to bring surface 18 near the inner wall of the lumen 22.
- Members 19 extend from surface 18 of the distal catheter body 29 to define the fenestrations 39.
- the step of expanding the distal catheter body may be performed before, after, or in combination with the step of introducing a fluent pre-stent material.
- the fluent pre-stent composition 26 capable of undergoing a transformation to a non-fluent stent composition 28 is introduced into the mold space created by the combination of the distal catheter body 29 and lumen 22.
- the fluent pre-stent composition 26 is introduced to the mold space via the catheter 20.
- the fluent pre-stent composition 26 can be transformed to the non-fluent stent composition 28 by a cross-linking or a thermoset activating energy delivery mechanism, such as, electromagnetic radiation (RF, microwave, violet, visible light, laser), ultrasound, or any other type of energy which can catalyze the transformation of the fluent pre-stent composition to a non-fluent stent composition.
- a chemical catalyst for causing the fluent pre-stent composition to become non-fluent can also be provided.
- the pre-stent composition 26 can also be provided as a heated thermoplastic. In any event, the fluent pre- stent composition 26 should have the necessary biocompatibility properties.
- the distal catheter body 29 includes a balloon 37 with pores 33 through which the fluent pre-stent composition is introduced to the mold space.
- the fluent pre-stent composition may be forced outward through the pores 33 by applying pressure to the fluent pre-stent composition within the catheter distal body 29.
- the fluent pre-stent composition can be forcibly deposited into any fissures and breaks in the vessel by radial expansion of pores 33.
- the expandable member 37 of the distal catheter body 29 can include a nonporous membrane having a multiplicity of holes 33 which are laser drilled or pin punched in the surface. The diameter of the holes determines the dispersion characteristics of the fluent pre-stent composition from the membrane.
- the membrane can be fabricated from a porous material through which the fluent pre-stent composition can be extruded upon the application of pneumatic or fluid pressure to the fluent pre-stent composition. While pneumatic pressure can be used to effect a radial expansion of the fluent pre-stent composition through the holes or pores, it is important that air does not enter the blood vessel.
- Other types of structures can also be incorporated into the distal catheter body 29 for delivering the fluent pre- stent composition.
- the expandable member 37 is a microporous membrane comprising a series of micropores 33 which are small enough to contain the pre-stent composition in a flowable or fluent state.
- the pores are configured such that upon the application of pressure to the internal volume of pre-stent composition contained within the flexible microporous membrane, the pores of the membrane will expand to enable the fluent pre-stent composition to be extruded through the pores and into the mold space surrounding the expanded membrane.
- Illustrated in Figure 31 is an energy source 36 for applying energy to the fluent pre-stent composition.
- energies which may be used in the present invention include, but are not limited to electromagnetic radiation (RF, microwave, ultraviolet light, visible light, laser), ultrasound, resistive heating, exothermic chemical heating, or any other type of energy which can initiate or accelerate the transformation of the fluent pre-stent composition.
- electromagnetic radiation RF, microwave, ultraviolet light, visible light, laser
- ultrasound resistive heating
- exothermic chemical heating or any other type of energy which can initiate or accelerate the transformation of the fluent pre-stent composition.
- the fluent pre-stent composition 26 is transformed to a non-fluent stent composition 28 which is in the shape of a stent. This transformation may optionally be initiated or accelerated by the application of supplemental energy.
- plaque 23 or some other material stenosing a body lumen may be compacted against the wall of the body lumen and may also become encapsulated within the non-fluent stent composition 28.
- the plaque may be intermingled with and incorporated with the non- fluent stent composition 28 as an interphase composite.
- the plaque can be removed prior to introduction of the fluent pre-stent composition and the formation of the stent.
- the non-fluent stent composition formed from the fluent pre-stent composition 26 should have the necessary structural and biocompatibility properties for use as a biological stent.
- the size of the distal catheter body 29 is reduced so that the catheter may be easily withdrawn from the region of the lumen 22. Meanwhile, the in situ formed fenestrated stent 28 with fenestrations 39 is left in position to structurally support the body lumen 22.
- the resulting fenestrated stent 28 should be made of a material that in combination with the fenestration design renders the stent sufficiently rigid to be capable of holding the body lumen 22 in a desired configuration.
- the fenestrated stent 28 should have a central lumen to allow fluid and biological material to flow through the stent and body lumen 22.
- the fenestrations should also be sized and positioned to allow fluid and biological material to flow between the body lumen and any vessels that branch from the body lumen 22 in which the stent is formed.
- the fluent pre-stent material can be mixed with therapeutic agents to promote healing, such as, for example, growth factors.
- therapeutic agents can also be provided in the pre-stent material to provide a desired therapeutic effect to the body lumen. These could include immunosuppressant agents such as cycloporin, adriamycin, and equivalents.
- agents for promoting cell growth of the endothelial tissue may be incorporated into the stent material.
- a wide variety of well known therapeutically useful pharmaceutical agents may be provided in the stent material for the prevention of restenosis.
- Such pharmaceutical agents include anticoagulants such as heparin, anti-platelet agents, fibrinolytic and thrombolytic agents as well as anti-inflammatory agents.
- anticoagulants such as heparin, anti-platelet agents, fibrinolytic and thrombolytic agents as well as anti-inflammatory agents.
- a conventional stent is preformed outside a body lumen, such as a blood vessel, and then pushed into place.
- a body lumen such as a blood vessel
- conventional preformed stents do not fill minute fissures and breaks in the body lumen and thus cannot be used to deliver therapeutic or healing agents to such sites.
- a conventional preformed stent does not conform with the body lumen.
- a conventional stent formed outside of the blood vessel does not conform to the unique characteristics or unique configuration of the particular site in the lumen wall where the stent is to be located.
- the pre-stent composition is protected against contamination from thrombogenic material as it is advanced within the vessel.
- the fluent pre-stent material lacks sufficient mechanical integrity to form a stent.
- trauma to the body lumen is substantially eliminated as compared to pre-formed stents.
- Stenosed tissues are known to be porous or to have numerous fissures.
- the placement of the fluent pre-stent composition at the site of a stenosed blood vessel provides the advantage of substantially eliminating the trauma normally associated with the placement of a rigid stent.
- the introduction of pre-stent composition in a fluent state provides a further advantage of being able to penetrate fissures and other breaks and unconformities in injured endovascular tissue with the pre-stent material.
- the fluent pre-stent composition interpenetrates the narrow fissures and openings in the endovascular wall and forms an inter-linked, anchoring structure which holds the stent firmly in place once it is solidified.
- the catheter 20 includes a guide wire 35 which includes a microwave antenna 39 for delivering microwave energy.
- the guide wire 35 may be slidable relative to the catheter body.
- the microwave antenna can be fixed relative to the catheter so that the catheter and the antenna slide on the guide wire.
- the antenna may also be contained in the catheter.
- the fluent pre-stent composition 26 preferably includes a composition 40 capable of absorbing microwave energy and thus can be used to heat the fluent pre-stent composition 26.
- an RF energy source 100 is coupled through a catheter tube 108 to an electrode 102 at a distal catheter body.
- the electrode 102 has a metallized or conductive microporous surface 104 (e.g., a metallized balloon) for conducting RF energy (shown by arrows) into adjacent fluent pre-stent material.
- the fluent pre-stent material includes a photo initiator/accelerator or photo polymer material which is changed from a fluent state to solid state upon the application of optical energy of a predetermined intensity, such as ultraviolet (UV) light of a predetermined wavelength, to effect polymerization for the change of the fluent pre-stent material to a non- fluent state.
- a source of optical energy 124 is conducted to the hollow catheter 108 through a fiber optic cable 126 in accordance with techniques which are well known.
- a conventional optical emitter 128 is positioned within the distal catheter body for irradiating the surrounding pre-stent composition with a source of optical energy necessary to achieve photo polymerization in accordance with techniques which are well known.
- the optical energy from the emitter 128 irradiates the surrounding pre-stent material equally and effects a substantially complete polymerization and solidification of the stent material about the distal catheter body which acts as a mold surface.
- the optical emitter 128 may comprise any conventional mechanism for emitting optical energy of a predetermined intensity to effect photo polymerization.
- the emitter 128 could be a microlens integrated onto a surface emitting laser.
- the microlens, as in the case of a conventional optical emitter may be disposed within the balloon 120 and can be irradiated by a collimated beam from a conventional laser through a fiber optic cable.
- Figure 4D shows an alternate method for applying activation energy to the fluent pre-stent material.
- an expandable, flexible catheter tube or balloon 140 comprises a microporous surface 142.
- a quantity of fluent pre-stent material is placed in the hollow catheter tube 140 and is extruded through the microporous surface 142 by the application of pneumatic or fluid pressure.
- An electrical source 144 is coupled through catheter tube 108 to a piezo electric crystal or ultrasound emitter 150 which is positioned within the expandable microporous catheter tube 140.
- the piezo electric crystal or ultrasonic transducer 150 is activated in accordance with techniques which are well known to apply an activation energy shown by the arrows in Figure 4D to the pre-stent composition which has been extruded through the microporous surface 142.
- a resistive heating element 160 for heating the fluent pre-stent composition may also be incorporated into the catheter. Once a sufficient amount of fluent pre-stent composition has been delivered from a fluent pre-stent composition source 161 , a source of electrical energy 162 activates the resistive heating element
- resistive heating may also be accomplished through a distributed array of malleable resistive heating elements provided over the distal catheter body in accordance with techniques which are well known.
- An array of resistive heating elements may be deposited, laser welded or otherwise provided over the outer surface of the balloon. This would have the advantage that the heating elements would be in direct contact with the mold surface formed by the distal catheter body and thus could provide direct and immediate conduction of heat energy to the pre-stent composition.
- the source of fluent pre-stent composition 161 includes a composition capable of effecting a change of state upon the application of energy above a predetermined threshold.
- This source of composition 161 can be completely contained within the distal catheter body.
- the source of composition 161 can be provided from a chamber or reservoir that is located external to the distal catheter body. In the latter case, the composition can be delivered to the distal catheter body through a line interconnecting the chamber or reservoir to the distal catheter body.
- the amount of fluent pre-stent composition which is introduced into the body lumen may be controlled by an active feedback control system.
- a microelectronic pressure sensor 164 may be disposed within the catheter for adaptive feedback control of the amount of fluent pre-stent composition to be passed through the catheter into the body lumen.
- the adaptive feedback control helps to ensure that the fluent pre-stent composition is evenly distributed as it is cast against the lumen wall.
- Known feedback methods are then used to control the amount of fluent pre-stent composition that is flowing through the catheter.
- the object is to equalize pressure over the surface of the distal catheter body to a predetermined threshold which would be compatible with expanding the fluent pre-stent composition into fissures in the surrounding lumen wall without damaging any lumen tissue.
- signals from the pressure sensor 164 are provided to a signal processor 166 for amplification in accordance with techniques which are well known.
- the amplified signals 168 from the signal processor 166 indicative that the predetermined pressure has been reached, are then provided to the source of pre-stent composition 161 in order to block further introduction of pre-stent composition into the system.
- signals 168 from the signal processor 166 may be applied to the electrical energy source 162 to activate the resistive heating element 160 and initiate delivery of energy to the pre-stent composition. This also has the effect of preventing additional pre-stent composition from entering the body lumen.
- the adaptive control system also prevents overexpansion of the distal catheter body and prevents excess pre-stent composition from entering the body lumen.
- Figures 5A and 5B show two alternate systems for advancing a catheter 100 to a desired region of a body lumen. Illustrated in Figure 5A is a guidewire system for advancing a catheter along a path of travel in a typical body lumen. A guidewire 102 is threaded through the catheter 100. The proximal end of catheter 100 is attached to a hollow catheter tube 104 for the introduction of a fluent stent composition into the catheter 100 as will be explained. The guidewire 102 is adapted to advance the catheter 100 along a path of travel within the lumen.
- FIG. 5B shows an alternate steerable system in which a porous catheter 100 is attached to a steerable catheter tube 105.
- the steerable catheter tube 105 comprises a distal end with a steering element 107.
- the proximal end of catheter tube 105 is connected to a source of fluent stent material for delivery to the porous catheter 100 in accordance with techniques which are well known.
- the catheter 100 is advanced along a path of travel in a body lumen by pressure applied to catheter tube 105.
- a steering element 107 can be a shape memory alloy activated device or other conventional steering device which enables the application of torque for steering catheter 100 in a particular direction when a junction is reached.
- Figures 6A and 6B depict a catheter 600 for molding a spiral- shaped fenestrated stent in situ.
- the catheter 600 provides a portion of the surface area of a mold space defined between the catheter 600 and a body lumen in which the catheter 600 is located.
- Figure 6A shows the device in both collapsed form and with a pair of occluding balloons 640 expanded (phantom lines).
- a balloon inflation lumen 610 conducts a liquid inflation medium to the balloons 640 through a pair of passageways 650.
- a fluent pre-stent composition lumen 620 conducts the fluent pre-stent composition to the mold space.
- the fluent pre-stent composition can reach the mold space through a plurality of microporous holes located in those portions of a central section 660 that are located in between the raised fenestration ribs 670, or, the fluent pre-stent composition can reach the mold space through a plurality of macro-porous holes 670 that are directly connected to the fluent pre-stent composition lumen 620.
- the interior of the control section 660 is filled with composition via holes 670 and the composition then passes from the interior of section 660 to the mold space via the microporous holes.
- Section 660 can be separately inflatable.
- Figure 6B shows a cross-section of the device taken proximal of the proximal balloon.
- the device includes three lumens at this point.
- a balloon inflation lumen 610 carries a medium to expand the balloons of the device and occlude the body lumen.
- a pre-stent composition lumen 620 conducts the composition that will be cast adjacent the tissue.
- the device also includes a guide wire lumen 630 through which a guide wire is passed.
- the guide wire lumen 630 provides a conduit for an RF power source in addition to encasing the guide wire that directs the device 600.
- Figure 7 shows a preferred device for forming a fenestrated stent in situ.
- a molded three-arm lure adaptor 710 includes a slurry lumen 715, a contrast/ guide wire port 720, and a balloon inflation lumen 725.
- the device includes a strain relief apparatus 730 such as a swivel bearing, bellows, plastic coupling, or other means for relieving strain between the adaptor and the rest of the apparatus.
- a strain relief apparatus 730 such as a swivel bearing, bellows, plastic coupling, or other means for relieving strain between the adaptor and the rest of the apparatus.
- the device includes proximal outer shaft 740.
- the proximal outer shaft 740 can be made of high density polyethylene, nylon, polyvinyl, polyester and silicone.
- the proximal outer shaft 740 may be connected to a distal outer shaft 750.
- the distal outer shaft 750 can be made of low density polyethylene.
- Located within both the proximal outer shaft 740 and the distal outer shaft 750 is an inner shaft 760.
- the inner shaft 760 can be made of low density polyethylene.
- the outer diameter of the proximal outer shaft 740 is less than 3.5f. in preferred embodiments, the outer diameter of the distal outer shaft 750 is less than 3.3f.
- An inner member 770 is located within the inner shaft 760.
- the inner member 770 can be a heavy duty nylon material, or any other material, suitable for use as a guide wire lumen.
- a guide wire (not shown) can be threaded through the member 770.
- a dual balloon 780 is held at one end.
- the mechanical junction between the outer shafts 740 and 750, as well as the junction between the outer shaft 750 and the balloon 780, as well as the end of the inner shaft 760 can all be transition points composed of lap joints 790.
- the balloon 780 includes an outer balloon 785.
- the outer balloon 785 is a peanut shaped conformal balloon. The functions of the outer balloon 785 are to occlude the lumen and provide an inner mold surface.
- the expanded shape of the outer balloon 785 is shown in phantom lines while the non-expanded shape (during insertion, positioning, and withdrawal) is shown in solid lines.
- the outer balloon 785 can be coated with gold.
- Within outer balloon 785 is an inner balloon 790.
- the inner balloon 790 is a non-conformed balloon.
- the function of the inner balloon 790 can be to break plaque or otherwise apply significant pressure to expand a body lumen.
- the inner member 770 passes through the middle of both inner balloon 790 and outer balloon 785 exiting at a nose 795.
- the outer balloon 785 is provided with a plurality of fluent pre-stent material lumen terminations 775 through which the fluent pre-stent composition can flow so as to fill a mold space defined in part by the expanded outer balloon 785.
- the fluent pre-stent composition can be provided to the terminations 775 through one or more individual lumens (not shown) or through a central manifold (not shown).
- Figures 8A and 8B show a double balloon structure 800 with an outer balloon 810 including a laminated RF electrode membrane. An inner non-porous angioplasty balloon 820 is located within the outer balloon 810.
- ure 8A shows fluent pre-stent composition 805 being directed into the outer balloon 810 and flowing through pores 825 in the outer balloon 810.
- the fluent pre-stent composition is provided through a lumen 812 via holes 815.
- the structure is threaded onto a guidewire 880 which can be distal the area to be treated.
- FIG. 8B shows the laminated RF electrode membrane 810 in more detail.
- An inner insulating layer 830 may be considered as a substrate for a conductive layer 840 which is sandwiched between a top insulating layer 850 and the inner insulating layer 830. All three layers are provided with through holes 860 for porosity. It should be noted that the top insulating layer 850 is provided with openings 870 coaxial with the through holes 860 for exposing the conductive RF layer. In this way,
- RF radiation 880 from the electrode is directed out from the balloon structure 800 toward the mold space. Relatively little RF radiation from the electrode emanates inward (toward the inner balloon).
- Figure 9 shows a catheter 900 for forming stents of variable lengths.
- Two independent microporous membrane covered balloons are independent microporous membrane covered balloons.
- variable length stent (920, 930) are arranged concentrially one inside the other. By sliding the balloons relative to each other, a variable length stent may be cast.
- Figures 10A and 10B show the distal catheter body 1060 of a catheter system having profusion valves and a bypass lumen. Blood flow 1000 through the body lumen 1050 and the distal catheter body
- 1060 is from left to right.
- Figure 10A depicts the distal catheter body 1060 in a collapsed (non-expanded) condition with proximal and distal profusion valves 1010, 1011 closed. In this configuration blood or other biological fluid is free to flow around the distal catheter body and through the body lumen
- Figure 10B depicts the distal catheter body in an expanded condition.
- blood flow within the body lumen 1050 around the distal catheter body 1060 is blocked.
- the proximal and distal profusion valves 1010, 1011 open. These valves are interconnected by a bypass lumen (not shown) which allows blood entering the open proximal valve 1010 to flow past the distal catheter body via the bypass lumen and out the distal valve 1011.
- a fluent pre-stent composition is introduced into the mold space 1030 through a plurality of holes 1040.
- the plurality of holes 1040 formed in the balloon 1020 and connect the mold space 1030 to a fluent pre-stent composition lumen located within the catheter.
- the fluent pre-stent composition After being introduced into the mold space 1030, the fluent pre-stent composition is transformed to a non-fluent stent composition, for example by curing the pre-stent composition with radio frequency energy or microwave energy.
- the particular pre-stent composition used will depend on the particular fluent - non-fluent transformation to be performed and the particular form of energy used.
- Figure 11 depicts a perfusion valve which allows blood or other biological fluid to flow while the balloon is expanded.
- Figures 12A and 12B illustrate alternative embodiments of a distal catheter body 29 with an aspiration port 47 and aspiration lumen 49.
- the distal catheter body 29 includes an inlet port 51 through which the fluent pre-stent composition is delivered within the mold space defined by the distal catheter body 29 and the vessel.
- the distal catheter body 29 includes an aspiration port through which excess pre-stent composition or other fluids can pass back into the distal catheter body 29.
- Figure 12A illustrates the aspiration port 47 as being adjacent the inlet port 51
- Figure 12B illustrates the aspiration port 47 as being coaxial with the inlet port 51. Alternate positionings of the inlet and aspiration ports are also intended to fall within the scope of the invention.
- the distal catheter body can include additional lumens and ports for delivering other materials within the mold space as well as for removing materials from the mold space.
- the distal catheter body can include a wash lumen and wash port for washing the mold space prior to or after stent formation.
- Figures 13A-13F illustrate a particular embodiment of the device and method of the present invention. As illustrated in this sequence, a device having a noncompliant interior balloon and an outer elastic (compliant) balloon is used to form a stent in situ.
- Figure 13A depicts an occluded blood vessel 1200.
- ure 13B depicts a distal catheter body 1220 advanced across the occlusion. Distal catheter body 1220 is positioned on a guide wire 1230.
- Figure 13C depicts a noncompliant interior balloon 1240 inflated to achieve dilation of the blood vessel 1200.
- Figure 13D depicts the interior noncompliant balloon 1240 deflated and being withdrawn to the left out of balloon 1250 (arrow pointing to left).
- Figure 13E depicts an outer elastic (compliant) balloon 1250 inflated to form a mold 1260 in which the fluent pre-stent composition is injected through a lumen 1270 that is attached to the surface of the elastic balloon 1250.
- Figure 13F depicts a finished stent 1280 formed by the conversion of the fluent pre- stent composition (delivered in the step depicted in Figure 13E) to a non-fluent stent material.
- Figure 14 depicts an in situ formed stent according to the present invention which has a desired degree of porosity, i.e., the stent includes a plurality of pores or holes in the wall of the stent which allow objects such as molecules, materials, cells, aggregates of a desired size range to traverse the stent.
- the pores in the stent may optionally be sufficiently large to allow any object normally found in the blood to traverse the stent.
- the stent 1300 includes a first end 1310, a second end 1320, and a cylindrical microporous wall 1330.
- the wall 1330 includes a plurality of micropores.
- the micropores can be provided in several different ways.
- One way of providing the micropores is to include a component in the fluent pre-stent composition which gets bioresorbed at a different, faster rate than the stent, leaving behind a network of channels where the component was dispersed in the stent when the stent was formed.
- the stent itself may or may not be bioresorbable.
- This bioresorbable material can optionally be a therapeutic agent which performs a therapeutic function in the process of being resorbed by the body.
- Another way in which the micropores can be provided in the stent is to include a foaming agent in the fluent pre-stent material.
- the foaming agent can be either a gas or a liquid. The action of the foaming agent creates the micropores.
- Figure 15 provides an expanded cross section of the wall 1330 of the stent illustrated in Figure 14.
- the wall 1330 is adjacent a vascular wall 1400.
- the wall 1330 is also adjacent a flow of blood 1410.
- the principal flow of the blood is depicted by the large arrowhead.
- blood and other materials can flow through the wall 1330 in either direction as depicted by the three curvaceous arrowheads.
- Nutrients in the blood 1410 can leach through the open cell structure of the wall 1330.
- the wall 1330 can supply necessary nutrients, proteins, cells and other biological materials to the inner surface of the stent through the wall.
- Figures 16A and 16B illustrate a stent fabricated to include electrodes. This stent can be used to promote electrolysis or can be used to prevent platelet and/or macroflange attachment.
- a bimetal stent can be constructed so as to exhibit an electrolysis effect. A first metal 1510 is placed in a spaced apart arrangement from a second metal 1520. If the electrolytic reduction potentials of the metal are sufficiently different, a voltage potential will be generated between the two metals.
- Figure 16B illustrates a composite stent constructed to contain electrically active materials. If the electrically active materials are separated from one another, such a stent can be used to act as a battery emitting a slight electrical charge to prevent platelet attachment.
- Figures 17A-17G illustrate a method for forming a fenestrated stent or a stent containing macropores in situ by including a separate phase in the stent that can be bioresorbed faster than the remainder of the stent.
- a separate phase in the stent that can be bioresorbed faster than the remainder of the stent.
- FIG 17A illustrates a stent 1610 having a generally corkscrew design.
- This stent can be formed by the catheter illustrated in Figure 17B.
- the catheter 1620 is connected to a guidewire 1625.
- the catheter 1620 includes a stent forming balloon 1630.
- the stent forming balloon 1630 includes a plurality of holes 1635 through which fluent pre-stent material can be exuded.
- a stretchable, dissolvable core 1640 is carried on the surface of the balloon 1630.
- Use of the catheter illustrated in Figure 17B to form the stent illustrated in Figure 17A is illustrated in Figures 17C-17G.
- the catheter illustrated in Figure 17B is inserted into a body lumen.
- the stent forming balloon 1630 is then expanded as illustrated in Figure 17D.
- Figure 17E shows an expanded cross section of a portion of the balloon depicted in Figure 17D.
- the core 1640 is adjacent to a wall 1650 that includes a surface of living tissue.
- a fluent pre-stent material 1655 is extruded through the holes 1635.
- the fluent pre-stent material is then rendered non-fluent to form the stent.
- the core 1640 and the cast stent material 1655 remain adjacent the wall 1650.
- the core material 1640 is resorbed, the stent illustrated in Figure 17G remains.
- Figures 18A-18D illustrate a device 1700 for forming a fenestrated stent which includes a flexible removable mold core 1710.
- the mold core 1710 expands against the intima of the body lumen in which it is located. Fluent pre-stent composition is then exuded through the holes in the balloon and converted in situ to a non-fluent stent composition.
- the balloon is removed, providing a central void through which the flexible removable mold core 1710 can be peeled away.
- the proximal end of the mold core 1710 is tethered to the distal end of the balloon.
- FIGs 19A-19B illustrate embodiments of a catheter where electromagnetic energy for converting the fluent pre-stent composition to the non-fluent stent composition is provided through a plurality of wave guides. This permits delivery of a higher amount of power to the distal end of the stent forming device.
- the wave guides can be microwave coaxial minicables.
- Figure 19A provides a cross section of the device.
- the device includes a guidewire channel 1810.
- the device also includes three microwave channels 1820.
- the device includes three fluid/inflation ports 1830.
- Figure 18B provides a prospective view of the device depicted in Figure 19A is illustrated.
- the device is threaded on a guide wire 1840.
- the microwave mini-coaxial cables 1850 are embedded in a balloon 1860.
- thermocouple junction 53 which reduces the amount of emf interference generated by a microwave field.
- the thermocouple junction 53 be positioned at an angle ⁇ between about 20° and 160° relative to the axis of the thermocouple 55, most preferably at an angle ⁇ of about 45°.
- Figures 21A-21C illustrate an embodiment of a multilumen balloon which can be used in the distal catheter body of the present invention.
- the lumens within the balloon can be used for a variety of functions including being used as inlet ports, aspiration ports, and washing ports.
- Figure 21A illustrates the distal catheter body 29 with cross sections A-A and B-B indicated.
- Figures 21 B and 21 C illustrate cross sections A-A and B-B respectively.
- each balloon is formed of a material 51 which defines two or more lumens 53.
- Cross-section A-A illustrates a section of the balloon which is not inflated.
- Cross-section B-B illustrates a section of the balloon which is inflated.
- Figures 22A-22D illustrate the operation of a device for simultaneously forming a plurality of stents.
- the stents are serially arranged along the longitudinal axis of a body lumen and spaced apart by occluding balloons.
- Figure 22A illustrates a device 1900 mounted upon a guide wire 1910.
- the device includes a plurality of occluding balloons 1920.
- the balloons 1920 are depicted in an expanded state in
- the balloons 1920 are depicted in a deflated state.
- the balloons 1920 are separated by metal rings.
- the proximal metal ring 1930 and the distal metal ring 1935 are non- perforated.
- the intermediate metal rings 1940 include a set of perforations through which fluent pre-stent material is extruded when the balloons 1920 are expanded and occluding the body lumen in which the stents are to be located.
- the balloons can be made of a silicone/elastomer.
- the device 1900 is depicted in an expanded state as it occludes a body lumen.
- a fluent pre-stent composition is deposited through the holes in the metal rings and electromagnetic energy (e.g., RF, MW, UV) is delivered to the deposited material.
- electromagnetic energy e.g., RF, MW, UV
- three finished stents are shown to be formed adjacent the tubular organ.
- compositions that can be converted from a fluent state to a non- fluent state have found general utility across industry groups.
- One mechanism for this conversion is via a free radical or cationic polymerization reaction.
- Such reactions often rely on a specific chemical composition to initiate the polymerization which are commonly called "initiators”.
- compounds such as benzoin ethers are often used;
- thermal cationic polymerizations compounds such as mineral acids are often used;
- photochemical cationic polymerizations compounds such as triphenyl sulfonium hexafluorophosphate are often used.
- two properties of the initiator are desired simultaneously: 1 ) a reasonable shelf-life or pot-life at a first lower temperature and 2) a rapid reaction rate at a second higher temperature.
- an initiator with such properties has been termed a “latent initiator” or a “latent catalyst”, and the difference between the first lower temperature for inactivity and the second higher temperature which activity occurs is called the "temperature window”.
- photochemical initiators possess an innate degree of latency since they become active only in the presence of light, in homogeneous systems, thermal initiators are bound by the constraints of finite reaction rates even at low temperatures. In general, the rate of change of a chemical reaction, including the initiator reaction and subsequent polymerization reactions contemplated here, are governed by the Arrhenius equation:
- E ⁇ is the energy of activation
- R is the gas constant
- T is the temperature in degrees Kelvin.
- Typical initiation reactions have E ⁇ values from 12 - 20 kcal/mole.
- the allowed difference in temperature is only of the order of 20 °C, as is the case here where the material will be stored at 25 °C and used at about 45 °C, then the difference in cure or setting times for a composition will be only about a factor of 4 - 8 times. Consequently, if a setting time of 2 minutes or less is desired, the pot- life of the composition will necessarily be at most 8 - 16 minutes, which is too short.
- a latent initiator system with a smaller temperature window that is inactive or minimally active at a first lower temperature but becomes active at a second, higher temperature that is relatively closer to the first temperature than in prior systems can be based on the following composition:
- the composition includes an energy susceptible material, preferably a solid, and a layer of a polymerization initiator surrounding and coating the energy susceptible material.
- the composition can include a second layer surrounding and coating the first layer of a material that has a phase transition, preferably a melting point, such that said transition occurs over a temperature range of no more than 5 °C and after completion of the phase transition allows communication between the initiator material and the bulk material to be polymerized.
- the instantaneous temperature at the core can be higher than that of the bulk composition. Since the polymerization initiator is in contact with the core, it may begin rapid initiation of polymerization while the bulk temperature is still too low a temperature for a rapid reaction.
- the initiator effectively will be protected from contact with the material to be polymerized by the crystalline structure of this outermost layer; hence the pot-life and/or shelf-life of the composition will be improved.
- the melting temperature is reached, a sharp phase transition will occur over a narrow temperature range which will then allow initiation and curing to commence as the heated initiator comes into contact with the polymerizable composition.
- the core energy susceptible material will be strongly interactive with microwave (MW) electromagnetic radiation.
- energy will be efficiently coupled directly to the core of the latent initiating particle without much heating of the surrounding material to be cured.
- the absorbed energy will quickly be released as heat, suitable for beginning thermal initiation and the phase transition of the outer layer.
- Suitable core materials are: ferric oxides, ferrites, graphite, amorphous carbon, lamp black, grey iron, iron, metals, ferrosilicons, solid polymer electrolytes.
- Suitable initiators are peroxides and azo compounds.
- Suitable phase transition materials are poly(ethylene oxides), main chain liquid crystal polymers, side chain liquid crystal polymers, poly(esters) such as poly(trimethylene glutarate), poly(trimethylene suberate), poly(trimethlyene adipate), poly(ethers) such as poly(tetrafluoroethylene oxide).
- iron oxide materials examples include, but are not limited to hematite ( ⁇ -Fe 2 O 3 ), maghemite (y-Fe 2 O 3 ), magnetite (Fe 3 O 4 ), geothite ( ⁇ - FeOOH), lepidocrocite (y-FeOOH), ferrihydrite, feroxyhyte ( ⁇ -FeOOH), akageneite ( ⁇ -FeOOH) graphite, and amorphous carbon and BaSO 4 .
- the microwave absorptive composition that constitutes a constituent of the fluent pre-stent material can be tantalum containing materials such as reduced metallic tantalum and/or tantalum oxides.
- a fluent pre-stent composition can be converted from a fluent to a non-fluent state by application of a threshold level of microwave energy. Additionally, the frequency of the MW energy can be specified or tuned to more effectively transfer energy to specific components of the composition. The ultimate result of such an energy transfer mediated by microwave radiation is to increase the temperature of the composition and effect the transformation.
- the fluent pre-stent composition can be converted to a non-fluent stent composition by the application of a threshold level of microwave energy.
- a threshold level of microwave energy Such materials for bioresorbable stents are described in U.S. Ser. No. 08/815,096 which is incorporated herein by reference.
- Non-bioresorbable or low bioresorbable materials are now envisioned which also can be converted from a fluent to a non- fluent state by application of a threshold level of energy. It is also envisioned to use both bioresorbable and non-bioresorbable materials together.
- Such non bioresorbable or low bioresorbable materials include monomers, oligomers and low molecular weight polymers that contain chemically reactive groups that can interact to form covalent bonds together in polymerization, cross-linking or chain extension processes.
- the mechanisms by which these covalent linkages are formed to include addition reactions mediated by free radical, neutral or cationic intermediates.
- free radical mediated addition reactions include thermally or photochemically initiated reaction of acrylate and methacrylate esters, vinyl groups such as styryl and maleic ester groups, and co-reactions of unsaturated esters and vinyl esters.
- cationic mediated addition reactions include thermally or photochemically initiated reaction of vinyl ethers.
- Addition reactions mediated by neutral species include the addition of active hydrogen compounds, such as alcohols or amines, to isocyanate containing species, and the addition of active hydrogen compounds to oxirane groups such as glycidyl ether and glycidyl ester groups (epoxide rings).
- active hydrogen compounds such as alcohols or amines
- oxirane groups such as glycidyl ether and glycidyl ester groups (epoxide rings).
- the bioresorbability of the final non-fluent products, as well as the overall mechanical integrity of the final stent composition, is largely determined and can be controlled by the selection of the residue comprising the non-reaction portion of the monomer, oligomer or low molecular weight reactive polymer.
- residues that are readily bioresorbable and biodegradable include those derived from simple hydroxyester, such as glycolide, lactide and caprolactone linkages, anyhydride linkages, spiroester and orthoester linkages.
- Intermediate biodegradability is achieved through incorporation of carbonate, amide or peptide, or urethane linkages.
- compositions can also include materials that have a high susceptibility and absorbance for microwave energy.
- materials include, but are not limited to, metal oxides, such as ferric oxide, and carboniferous materials, such as acetylene black and graphite, or hydroxyl containing materials, such as alcohols or water.
- a thermally activated free radical initiator and optionally an accelerator may be included in the composition.
- thermal initiation materials include, but are not limited to, a peroxide material like benzoyl peroxide or lauroyl peroxide or ammonium persulfate, or an azo material, such as azo bis(isobutylnitrile) (AIBN, Vazo 64).
- Accelerator materials include, but are not limited to, reductants such as amines, like triethanol amine (TEOA), alpha hydroxy ketones, like benzoin and acetoin, and ascorbic acid and derivatives.
- the fluent pre-stent material may be formed of one or more components which can be transformed from a fluent to a non-fluent state.
- the fluent pre-stent material is a single component which undergoes a liquid to solid phase change.
- the fluent pre-stent composition is a single component which undergoes a chemical reaction to form a different, non-fluent composition. This chemical reaction may be stimulated by the introduction of a catalyst and/or energy to trigger the transformation.
- the fluent pre-stent composition is formed of two or more components. These components may react with each other to form a non-fluent composition upon contact, or with the assistance of a chemical catalyst and/or energy.
- the conditions under which the fluent pre-stent composition is converted to a non-fluent stent composition can be used to govern the final physical properties of the stent, such as morphology and modulus.
- the mold cavity formed by the balloon surface and surrounding endovascular wall can function much as a batch reactor for conducting a chemical or photochemical reaction. Reaction parameters such as the pressure, temperature and times for injecting reactor fluids into the mold can be controlled in accordance with techniques which are well known to ensure that a desired modulus, homogeneity, or physical property is imparted to the stent being formed in the mold.
- the fluent pre-stent composition can be formulated from any one or more components which have the necessary biocompatible properties and which can be converted in situ to a non-fluent stent composition.
- the fluent pre-stent composition is preferably capable of interlinking with fissures and breaks in living tissue.
- the fluent pre-stent composition also preferably can penetrate pores of living tissue and can repair an endovascular luminal surface.
- a preferred fluent stent composition that may be used in the present invention includes a protein, glycoprotein and/or polysaccharide.
- the fluent pre-stent composition also preferably includes a liquid vehicle electrolyte capable of dissolving or suspending the protein, glycoprotein or polysaccharide.
- the liquid vehicle electrolyte can include an aqueous solution with sufficient ionic strength to conduct electric current or RF energy.
- the liquid vehicle electrolyte comprises water and ionized inorganic or organic based salts or poly-salts.
- the fluent pre-stent composition also includes an insoluble network reinforcement agent.
- the fluent pre-stent composition also includes adjuvants to promote wound healing.
- the fluent pre-stent composition also includes adjuvants which are preferentially resorbed by the body, leaving behind a stent of certain porosity.
- the fluent pre-stent composition also includes an agent capable of delivering radioactive energy that can be used to prevent restenosis where the stent formed using the material is positioned.
- an agent capable of delivering radioactive energy that can be used to prevent restenosis where the stent formed using the material is positioned.
- Any radioactive material may be used.
- radionucleotides which may be used include, but are not limited to iodine, iridium, cesium, and yttrium.
- the agent may optionally be an alpha particle emitter, or a beta emitter, and is preferably a low energy beta emitter with a short half life.
- the agent delivers a form of radioactive energy in response to an external stimuli.
- the agent is encapsulated, preferably within polyethylene oxide or polyvinyl alcohol.
- Figure 23 illustrates a stent 2002 formed in situ in a vessel 2004 which includes a radio active isotope 2006, a microwave absorptive composition 2008, and a microwave shield 2010 for insulating the vessel from microwave energy.
- compositions which can be used for the stent composition include a matrix material comprising a protein, glyco-protein or polysaccharide: collagen, fibrin, elastin, fibronectin, vironectin, aglin, albumin, laminin, gelatin, cellulose, modified cellulose, starch, modified starch, synthetic polypeptide; acetylated, sulfonated or phosphorylated collagen, glycosaminoglycans (heparin, heparan, dermatan, chrondoin sulfate).
- the composition can include a liquid vehicle electrolyte comprising aqueous saline or calcium chloride.
- the composition can include a reinforcing material comprising poly(lactide), poly (glycolide), poly (lactide)-co-(glycolide), poly
- caprolactone poly (betahydroxtbutylate), a poly (anhydride), or a poly (orthoester).
- a liquid vehicle electrolyte can be advantageously used if RF energy is the source of activation energy applied to effect the change of the pre-stent composition from a fluent to a non-fluent state. If the ionic strength of aqueous saline or calcium chloride is high enough, the electrolyte can also assist in lysing some of the cells. This advantageously may provide a tissue surface that is more readily interpenetrated and bondable by the stent composition as it becomes non-fluent.
- the matrix materials and liquid vehicle electrolyte are the compositions which most often can be used for the pre-stent composition.
- a fluent pre-stent composition that would be expected to respond to RF energy and effect a change of state from a fluent to a non-fluent composition preferably should preferably have the following properties.
- the fleunt pre-stent composition preferably undergoes a change of state from a fluent state to a non-fluent state upon the application of activation energy of a predetermined threshold for initiating the change of state.
- the change of state is effected by a microstructural transformation such as the changing of a lattice network in response to a temperature above the activation threshold as is well known.
- the activation energy comprises optical energy having a sufficient intensity to effect photo initiation and/or photo polymerization in accordance with techniques which are well known. If the material is soluble, it should become insoluble or merely swellable in the vehicle electrolyte.
- the fluent pre-stent composition is insoluble, but a suspension or emulsion, it should become coagulated and not be resuspendable when in solid form.
- the preferred material should become more elastic with greater out of phase shear stress response. A net volume contraction should be observable due to loss of the aqueous vehicle to tissue and air as well as conformational changes and chemical shrinkage from cross-linking.
- the fluent pre-stent material includes magnesium sulfate (MgSO 4 ) which serves to dilate the vessel wall to facilitate expansion of the vessel wall.
- MgSO 4 magnesium sulfate
- the magnesium sulfate may also be used to enhance the conductivity of the fluent pre-stent material, for example when RF energy is used.
- the material that comprises the body of the stent consists of four components; a protein; a glycoprotein or polysaccharide, a liquid vehicle electrolyte added for conducting RF energy to effect the change of state from a flowable material to a solid, an insoluble yet bioresorbable network reinforcement agent and an adjuvant to promote wound healing such as heparin or its derivatives.
- a practical application of the present invention that has value within the technological arts is the treatment of stenosed or otherwise injured endovascular wall of a vas. Further, the present invention is useful in conjunction with the treatment of other lumen, or the like. There are virtually innumerable uses for the present invention, all of which need not be detailed here.
- catheter disclosed is described as a physical separate module, it will be manifest that the catheter may be integrated into other apparatus with which it is associated. Further, all the disclosed elements and features of each disclosed embodiment can be combined with, or substituted for, the disclosed elements and features of every other disclosed embodiment except where such elements or features are mutually exclusive.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/004779 WO1998040033A2 (en) | 1997-03-12 | 1998-03-12 | In situ formed stent |
AU66983/98A AU6698398A (en) | 1997-03-12 | 1998-03-12 | (in situ) formed stent |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81509697A | 1997-03-12 | 1997-03-12 | |
US08/815,096 | 1997-03-12 | ||
US85732397A | 1997-05-16 | 1997-05-16 | |
US08/857,323 | 1997-05-16 | ||
US98224797A | 1997-12-01 | 1997-12-01 | |
US98212097A | 1997-12-01 | 1997-12-01 | |
US08/982,246 US6039757A (en) | 1997-03-12 | 1997-12-01 | In situ formed fenestrated stent |
US08/982,246 | 1997-12-01 | ||
US08/984,481 | 1997-12-01 | ||
US08/984,481 US5899917A (en) | 1997-03-12 | 1997-12-01 | Method for forming a stent in situ |
US08/982,247 | 1997-12-01 | ||
US08/982,120 | 1997-12-01 | ||
PCT/US1998/004779 WO1998040033A2 (en) | 1997-03-12 | 1998-03-12 | In situ formed stent |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998040033A2 true WO1998040033A2 (en) | 1998-09-17 |
WO1998040033A3 WO1998040033A3 (en) | 1999-01-14 |
WO1998040033A9 WO1998040033A9 (en) | 1999-02-18 |
Family
ID=39618018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/004779 WO1998040033A2 (en) | 1997-03-12 | 1998-03-12 | In situ formed stent |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6698398A (en) |
WO (1) | WO1998040033A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006047191A1 (en) * | 2004-10-21 | 2006-05-04 | Boston Scientific Limited | Medical implant with average surface charge density |
EP2052699A1 (en) * | 2006-07-20 | 2009-04-29 | Obschestvo s ogranichennoi otvetstvennostju ¨Roscardioinvest¨ | Cusp for artificial cardiac valve and a method for the production thereof |
EP2254530A2 (en) * | 2008-02-25 | 2010-12-01 | Mayo Foundation for Medical Education and Research | Conformable stents and methods for making |
WO2014022644A1 (en) * | 2012-08-03 | 2014-02-06 | Muffin Incorporated | Weeping balloon catheter with ultrasound element |
US8932317B2 (en) | 1999-06-02 | 2015-01-13 | Microvention, Inc. | Intracorporeal occlusive device and method |
WO2015184154A1 (en) * | 2014-05-28 | 2015-12-03 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
US10299755B2 (en) | 2007-12-21 | 2019-05-28 | Microvention, Inc. | System and method for locating detachment zone of a detachable implant |
US10517604B2 (en) | 2010-04-14 | 2019-12-31 | Microvention, Inc. | Implant delivery device |
KR20200123338A (en) * | 2019-04-18 | 2020-10-29 | 주식회사 엠아이텍 | Stent delivery device |
KR20210073866A (en) * | 2019-12-11 | 2021-06-21 | 건양대학교산학협력단 | Inserting device of stent |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009012353A2 (en) | 2007-07-19 | 2009-01-22 | Boston Scientific Limited | Endoprosthesis having a non-fouling surface |
WO2009020520A1 (en) | 2007-08-03 | 2009-02-12 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8192480B2 (en) | 2007-12-21 | 2012-06-05 | Microvention, Inc. | System and method of detecting implant detachment |
WO2009131911A2 (en) | 2008-04-22 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100429A (en) | 1989-04-28 | 1992-03-31 | C. R. Bard, Inc. | Endovascular stent and delivery system |
US5334201A (en) | 1993-03-12 | 1994-08-02 | Cowan Kevin P | Permanent stent made of a cross linkable material |
US5344444A (en) | 1991-07-03 | 1994-09-06 | Industrial Research B.V. | Expandable ring, cylinder or sleeve which can be made non-deformable |
US5443495A (en) | 1993-09-17 | 1995-08-22 | Scimed Lifesystems Inc. | Polymerization angioplasty balloon implant device |
US5464419A (en) | 1993-03-22 | 1995-11-07 | Industrial Research B.V. | Expandable hollow sleeve for the local support and/or reinforcement of a body vessel, and method for the fabrication thereof |
US5599307A (en) | 1993-07-26 | 1997-02-04 | Loyola University Of Chicago | Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities |
US5634946A (en) | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4191989A (en) * | 1988-08-24 | 1990-03-23 | Marvin J. Slepian | Biodegradable polymeric endoluminal sealing |
US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
US5591199A (en) * | 1995-06-07 | 1997-01-07 | Porter; Christopher H. | Curable fiber composite stent and delivery system |
-
1998
- 1998-03-12 WO PCT/US1998/004779 patent/WO1998040033A2/en active Application Filing
- 1998-03-12 AU AU66983/98A patent/AU6698398A/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5634946A (en) | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
US5100429A (en) | 1989-04-28 | 1992-03-31 | C. R. Bard, Inc. | Endovascular stent and delivery system |
US5344444A (en) | 1991-07-03 | 1994-09-06 | Industrial Research B.V. | Expandable ring, cylinder or sleeve which can be made non-deformable |
US5334201A (en) | 1993-03-12 | 1994-08-02 | Cowan Kevin P | Permanent stent made of a cross linkable material |
US5464419A (en) | 1993-03-22 | 1995-11-07 | Industrial Research B.V. | Expandable hollow sleeve for the local support and/or reinforcement of a body vessel, and method for the fabrication thereof |
US5529653A (en) | 1993-03-22 | 1996-06-25 | Industrial Research B.V. | Expandable hollow sleeve for the local support and/or reinforcement of a body vessel, and method for the fabrication thereof |
US5599307A (en) | 1993-07-26 | 1997-02-04 | Loyola University Of Chicago | Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities |
US5443495A (en) | 1993-09-17 | 1995-08-22 | Scimed Lifesystems Inc. | Polymerization angioplasty balloon implant device |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8932317B2 (en) | 1999-06-02 | 2015-01-13 | Microvention, Inc. | Intracorporeal occlusive device and method |
US9788840B2 (en) | 1999-06-02 | 2017-10-17 | Michael P. Marks | Intracorporeal occlusive device and method |
US9526505B2 (en) | 1999-06-02 | 2016-12-27 | Microvention, Inc. | Intracorporeal occlusive device and method |
WO2006047191A1 (en) * | 2004-10-21 | 2006-05-04 | Boston Scientific Limited | Medical implant with average surface charge density |
EP2052699A1 (en) * | 2006-07-20 | 2009-04-29 | Obschestvo s ogranichennoi otvetstvennostju ¨Roscardioinvest¨ | Cusp for artificial cardiac valve and a method for the production thereof |
EP2052699A4 (en) * | 2006-07-20 | 2009-10-21 | Obschestvo S Ogranichennoi Otv | Cusp for artificial cardiac valve and a method for the production thereof |
US10299755B2 (en) | 2007-12-21 | 2019-05-28 | Microvention, Inc. | System and method for locating detachment zone of a detachable implant |
US8388674B2 (en) | 2008-02-25 | 2013-03-05 | Mayo Foundation For Medical Education And Research | Conformable stents and methods for making |
EP2254530A2 (en) * | 2008-02-25 | 2010-12-01 | Mayo Foundation for Medical Education and Research | Conformable stents and methods for making |
EP2254530A4 (en) * | 2008-02-25 | 2012-10-24 | Mayo Foundation | Conformable stents and methods for making |
JP2011512909A (en) * | 2008-02-25 | 2011-04-28 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Shape-compatible stent and manufacturing method |
US11357513B2 (en) | 2010-04-14 | 2022-06-14 | Microvention, Inc. | Implant delivery device |
US10517604B2 (en) | 2010-04-14 | 2019-12-31 | Microvention, Inc. | Implant delivery device |
US10328290B2 (en) | 2012-08-03 | 2019-06-25 | Muffin Incorporated | Weeping balloon catheter with ultrasound element |
WO2014022644A1 (en) * | 2012-08-03 | 2014-02-06 | Muffin Incorporated | Weeping balloon catheter with ultrasound element |
US9913649B2 (en) | 2014-05-28 | 2018-03-13 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
KR101886551B1 (en) * | 2014-05-28 | 2018-08-07 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Catheter with radiofrequency cutting tip and heated balloon |
KR20180089559A (en) * | 2014-05-28 | 2018-08-08 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Catheter with radiofrequency cutting tip and heated balloon |
EP3360488A3 (en) * | 2014-05-28 | 2018-11-21 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
KR101946222B1 (en) | 2014-05-28 | 2019-04-17 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Catheter with radiofrequency cutting tip and heated balloon |
AU2015266924B2 (en) * | 2014-05-28 | 2017-11-09 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
KR20170003586A (en) * | 2014-05-28 | 2017-01-09 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Catheter with radiofrequency cutting tip and heated balloon |
US11000283B2 (en) | 2014-05-28 | 2021-05-11 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
WO2015184154A1 (en) * | 2014-05-28 | 2015-12-03 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
KR20200123338A (en) * | 2019-04-18 | 2020-10-29 | 주식회사 엠아이텍 | Stent delivery device |
KR20210073866A (en) * | 2019-12-11 | 2021-06-21 | 건양대학교산학협력단 | Inserting device of stent |
Also Published As
Publication number | Publication date |
---|---|
WO1998040033A3 (en) | 1999-01-14 |
AU6698398A (en) | 1998-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6039757A (en) | In situ formed fenestrated stent | |
US5092841A (en) | Method for treating an arterial wall injured during angioplasty | |
WO1998040034A9 (en) | A radiopaque, bioresorbable stent, created in situ | |
JPH04501670A (en) | Intraluminal sealing with biodegradable polymeric materials | |
WO1998040033A2 (en) | In situ formed stent | |
WO1998040033A9 (en) | In situ formed stent | |
US5199951A (en) | Method of drug application in a transporting medium to an arterial wall injured during angioplasty | |
US8591782B2 (en) | Process for producing stent | |
JP2940859B2 (en) | Shape memory lock mechanism for intravascular stent | |
US7727184B2 (en) | Biological revascularization | |
US5547472A (en) | Catheter with medicament injection pores | |
US7645259B2 (en) | Multi-function catheter and use thereof | |
EP2833844B1 (en) | Control of balloon inflation rate during deployment of scaffold | |
CA2193805C (en) | Devices and methods for application of intraluminal photopolymerized gels | |
US5779673A (en) | Devices and methods for application of intraluminal photopolymerized gels | |
JP3659664B2 (en) | Medical tube | |
US20080140002A1 (en) | System for delivery of biologically active substances with actuating three dimensional surface | |
WO1995007667A1 (en) | Polymerizable angioplasty balloon implant device and method | |
JPH11506957A (en) | Curable fiber composite stent and its forming arrangement | |
JP2008541936A (en) | In vivo stent formation | |
JP2001501506A (en) | Stent lining | |
CN113856000A (en) | Isolated stent implantation using dual lumen aspiration | |
EP1567090B1 (en) | Photo curable endoprosthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/29-29/29, DRAWINGS, REPLACED BY NEW PAGES 1/29-29/29; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP Ref document number: 1998539770 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase in: |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |